ArticleIJU case reports2025

Editorial Comment on "Efficacy of pembrolizumab plus lenvatinib as first-line treatment for metastatic renal cell carcinoma with multiple brain metastases".

Manabu KatoPubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.